A new study has revealed that blood-based biomarkers can enable simple, accurate Tuberculosis (TB) tests for diagnosis and monitoring.
Emory Health Sciences’ researchers have identified blood-based biomarkers in patients with active tuberculosis (ATB) that could lead to new blood-based diagnostics and tools for monitoring treatment response and cure.
The research team sought to identify blood-based biomarkers in patients with ATB. They hypothesized that expression of immune activation markers on Mycobacterium tuberculosis (Mtb)-specific T cells would be associated with the amount of bacteria present within an infected individual and could thus provide a gauge of Mtb, the bacterium that causes TB, infection.
They reasoned that individuals with ATB disease would harbor higher frequencies of immune markers CD38+/HLA-DR+/Ki-67+ in their blood than those with latent Mtb infection (LTBI) or those who had cleared their infection after successful treatment.
Lead researcher Jyothi Rengarajan said that in order to reduce the burden of TB globally, identifying and treating all TB cases is a critical priority, but accurate diagnosis of active TB disease remains challenging and methods for monitoring how well a patient responds to the six-to nine-month long, four-drug regimen of anti-TB treatment, are highly inadequate.
Rengarajan added that in this study, they have identified T cell biomarkers that accurately identify ATB patients.
The findings show that blood-based biomarkers have the potential to accurately diagnose ATB and discriminate between ATB and LTBI, noted Rengarajan. They are now interested in evaluating these biomarkers in larger studies in TB-endemic areas and across a roader spectrum of Mtb infection, including extra-pulmonary TB and in HIV-infected populations.
Rengarajan concluded that blood-based biomarkers will be particularly useful in situations where sputum-based diagnosis of TB is more difficult. Because these biomarkers provide a gauge of Mtb load within individuals, they could also have utility as surrogate markers of treatment response and as predictors of treatment efficacy, cure and relapse in patients undergoing treatment for drug-susceptible as well as drug-resistant TB.
